CyPath Sales Surge, but Dilution Risk Keeps BIAF a Wait

What happened

bioAffinity Technologies announced that CyPath Lung sales more than doubled through the third quarter of 2026 compared to 2025, consistent with earlier momentum but lacking granularity on total revenue or cash burn. The DeepValue report had already flagged rapid CyPath adoption—Q1 revenue up 114% to $361K and April units up nearly 300%—yet total company revenue fell 36% in Q1 and operating cash burn hit $3.23M. A June equity raise netted only $2.6M and increased shares outstanding from 4.5M to 6.28M, highlighting serial dilution. This press release provides no new information on profitability, liquidity, or institutional conversion, leaving the fundamental picture unchanged. The stock remains a 'wait' until full Q2 and Q3 filings prove that CyPath growth can outpace continued financing needs.

Implication

Investors should view this as a marketing update rather than a fundamental inflection. The key variables remain total revenue growth, quarterly cash burn reduction, and avoidance of further near-term dilution. Until Q2 and Q3 filings confirm CyPath revenue above $500K, consolidated growth, and burn below $2.5M, the risk/reward is unattractive. A more attractive entry exists near $0.70 if financials disappoint, while a break above $1.10 would require proof of institutional adoption and improved unit economics. Maintain a wait and reassess after the next 10-Q.

Thesis delta

The fundamental thesis is unchanged. The press release confirms CyPath momentum but provides no new data on profitability, cash burn, or dilution. The WAIT rating and valuation scenarios remain appropriate until full quarterly results are released.